Ruonan Xu

TL;DR: Th17 cells are highly enriched in both peripheral blood and liver of CHB patients, and exhibit a potential to exacerbate liver damage during chronic HBV infection.

TL;DR: Umbilical cord‐derived MSC transfusion is clinically safe and could improve liver function and reduce ascites in patients with decompensated LC, therefore, UC‐MSC transfusion might present a novel therapeutic approach for patients with deconsecrated LC.

TL;DR: The UC‐MSC transfusions significantly increased the survival rates in ACLF patients; reduced the model for end‐stage liver disease scores; increased serum albumin, cholinesterase, and prothrombin activity; and increased platelet counts.

TL;DR: Evaluated data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated, and phase 2/3 randomized, controlled, double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC- MSCs to reduce deaths and improve long- term treatment outcomes.

TL;DR: This review summarizes novel concepts of neutrophil-mediated liver injury that are based on current clinical and animal model studies and indicates that neutrophils are a major innate immune cell subset in humans.